Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Canine cancer study aimed at improving survival for humans and dogs


News provided by

Canadian Cancer Society (National Office)

Apr 16, 2014, 00:01 ET

Share this article

Share toX

Share this article

Share toX

New research involving man's best friend could provide important insights into why some human cancers become resistant to treatment

TORONTO, April 16, 2014 /CNW/ - With a $165,000 Innovation Grant from the Canadian Cancer Society, a University of Saskatchewan research team will treat dogs with drug-resistant lymphoma to uncover the reasons for this resistance and to identify ways to reverse it. Although scientists have identified the various processes involved in anticancer drug resistance, it remains a major problem and effective treatment is lacking.

"The cancer we're studying - lymphoma - is very similar to human non-Hodgkin lymphoma. It's spontaneous and responds to drug therapy. The same therapies are used, and both the canine and human cancers develop similar drug resistance," says study leader Dr Troy Harkness, a molecular geneticist and professor at the university. "Because dogs age faster than humans, their disease advances more quickly and we are able to observe results that much sooner."

The dogs participating in the study have already been diagnosed with drug-resistant lymphoma. They will receive treatment on an outpatient basis and the results of their treatment will be analyzed as part of this study.

For over a decade, Dr Harkness' research has focused primarily on cancers that no longer respond to treatment. Last year his research team began studying the effect of Metformin on dogs with drug-resistant lymphoma. Metformin is a drug that has long been used to treat type 2 diabetes. Metformin is thought to have anti-cancer properties, potentially by decreasing the risk of cancer and may also have an impact on existing cancers.

In this study, the researchers will combine Metformin with standard chemotherapy to test if this will re-sensitize the dogs to anticancer drugs. To unravel how the drug is affecting cancer, the researchers will identify molecular markers of drug resistance, test whether Metformin can return these markers to normal, and build a database of the genetic changes associated with the onset of canine lymphoma. The Saskatchewan researchers are the first in the world to look at how Metformin may work to reverse lymphoma drug resistance in dogs.

The canine patients are being cared for by a team of veterinarians (Drs Val MacDonald and Casey Gaunt at the Western College of Veterinary Medicine). The unique team of scientists also includes experts in medical endocrinology (Dr Terra Arnason) and bioinformatics (Dr Tony Kusalik). The multidisciplinary team is essential to understanding the genetic activity - which genes are turned on or off - and identifying potential targets for new drug treatments.

"Whatever we find in dogs, we predict will be similar in humans. If we find the right combination, we may be able to predict earlier when multiple drug resistance is happening, target these individuals and start with a new treatment that may ultimately be more effective," Dr Harkness says.

The team should collect enough data within 2 years to have a good idea whether Metformin assists in reversing drug resistance. Then a similar study could be run with people to apply what the team has learned in dogs.

Watch our video about Dr Harkness' research

"Expanding our knowledge about cancer can come from unique places, and that's one of the goals of our Innovation Grants program - supporting projects that approach cancer research from different perspectives," says Dr Siân Bevan, Director, Research, Canadian Cancer Society. "Dr Harkness' research could lead to a better understanding of how multi-drug resistance occurs and could lead to improved ways to detect this resistance at earlier stages, identify targets for new treatments and help these patients live longer."

The Society's Innovation Grants program supports innovation, creative problem solving and unconventional concepts, approaches or methodologies in cancer research. This year the Society has awarded 46 grants worth almost $9 million.

Below are a few of the other new Innovation Grants. A complete list is available on cancer.ca.

Dr Kevin Petrecca, McGill University, Montreal, $170,500 - Dr Petrecca is studying the genetics involved in the spread of the most common adult brain cancer, glioblastoma. He has found that the gene DRR is an important driver of cancer spread. He is now developing a gene-silencing treatment to block DRR expression and testing its effectiveness in a preclinical mouse model.

Dr Petrecca's grant has been named the Brooke's Donkeys Innovation Grant of the Canadian Cancer Society in recognition of the outstanding efforts of Brooke's Donkeys, one of the top Relay for Life fundraising teams in Canada for the last 3 years. Since 2011, they have raised $200,000.

Dr Wan Lam, BC Cancer Research Centre, Vancouver, $200,000 - Lung cancer is one of the deadliest cancers, and its treatment is associated with adverse effects. Dr Lam is studying the role of immune cells in lung cancer and a new type of immunotherapy that targets a tumour's microenvironment. His team will collect samples from healthy individuals and compare those with samples from lung cancer patients to see differences in the types of immune cells and how they work. They will test whether a new treatment that can target specific organs, known as site-specific immunomodulation (SSI), triggers an anti-tumour immune response in lung cancers. This could lead to new therapies for lung cancer.

Dr Sabine Mai, University of Manitoba, Winnipeg, $198,210 - When normal cells become cancer cells, their DNA architecture - the way genetic material is organized in cells - changes. Dr Mai is using super-resolution microscopy to compare normal cells to cancerous ones and identify the architectural changes that take place. This work will help build a better understanding of how cancer develops and identify new structural biomarkers to define cancer cells and stages.

Dr Shana Kelley, University of Toronto, $200,000 - Cancers are more easily treated when they are diagnosed early, but some cancers - such as those in the brain - are hard to detect at an early stage. Dr Kelley is developing a novel way to diagnose cancers early through a simple blood test. Taking advantage of new knowledge that tumours release microparticles, she is developing a device to collect these particles and analyze the information they carry about the tumour. This device could be used to identify early signs that a tumour is present in the body and pinpoint aggressive cancers needing immediate treatment.

Through our generous donors and gold-standard peer-review process, the Canadian Cancer Society funds the best cancer research in Canada. Our funded researchers work in universities, hospitals and research centres across the country and are mapping new ways to change cancer forever. For more information, visit cancer.ca or call our toll-free, bilingual Cancer Information Service at 1-888-939-3333 (TTY 1-866-786-3934).

Image with caption: "Dr. Troy Harkness has received a Canadian Cancer Society Innovation Grant to investigate a new strategy to overcome treatment resistance in cancers. (CNW Group/Canadian Cancer Society (National Office))". Image available at: http://photos.newswire.ca/images/download/20140416_C4010_PHOTO_EN_39331.jpg

Image with caption: "Canadian Cancer Society (CNW Group/Canadian Cancer Society (National Office))". Image available at: http://photos.newswire.ca/images/download/20140416_C4010_PHOTO_EN_39332.jpg

SOURCE: Canadian Cancer Society (National Office)

Karen Ramlall
Manager, Research Communications
Canadian Cancer Society
[email protected]
416-934-5341

Modal title

Organization Profile

Canadian Cancer Society (National Office)

    Also from this source

  • Expert report an impressive first step to reimagine and modernize the Canadian Task Force on Preventive Health Care

  • Media Advisory -- The Canadian Cancer Society's Relay For Life returns to 17 communities across Quebec on June 7 and 14

  • World-first clinical trial confirms exercise improves survival for colon cancer

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.